AbbVie. has filed a patent for a process to prepare a specific compound for treating rheumatoid arthritis. The patent also covers solid state forms, pharmaceutical compositions, synthesis methods, and products-by-process. Claims 1-116 have been canceled. GlobalData’s report on AbbVie gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights AbbVie Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on AbbVie, Peptide pharmacophores was a key innovation area identified from patents. AbbVie's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of rheumatoid arthritis with specific pharmaceutical composition

Source: United States Patent and Trademark Office (USPTO). Credit: AbbVie Inc

The patent application (Publication Number: US20240034740A1) describes an extended-release pharmaceutical tablet designed to deliver a specific active ingredient, (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, in a controlled manner. The tablet includes this active ingredient, an acidic pH modifier, and a release control polymer. The release control polymer is specified as a hydrophilic polymer, while the acidic pH modifier is an organic acid, with tartaric acid being a specific example mentioned in the claims.

Furthermore, the patent application details the performance of the extended-release tablet in different environments. It highlights that the tablet is designed to release the active ingredient consistently, regardless of the pH of the environment it enters. Specifically, the tablet is expected to release the active ingredient at a rate independent of the pH, even in environments with a pH range from about 1.2 to 6.8. The dissolution characteristics of the tablet are also specified, indicating that when tested in a standard USP rotating paddle apparatus under specific conditions, the tablet should dissolve a significant portion of the active ingredient within a defined timeframe, showcasing its extended-release properties.

To know more about GlobalData’s detailed insights on AbbVie, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies